These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8764799)

  • 1. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma.
    Rulo AH; Greve EL; Geijssen HC; Hoyng PF
    Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
    Rulo AH; Greve EL; Hoyng PF
    Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure.
    Lusky M; Ticho U; Glovinsky J; Weinberger D; Nesher R; Yassur Y; Melamed S
    Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
    Camras CB
    Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.
    Diestelhorst M; Roters S; Krieglstein GK
    Graefes Arch Clin Exp Ophthalmol; 1997 Jan; 235(1):20-6. PubMed ID: 9034838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S; Sheth GP; Hitchings RA; Stjernschantz J
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
    Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
    Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
    Alm A; Stjernschantz J
    Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
    Watson P; Stjernschantz J
    Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
    Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
    Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.